Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AR | P10275 | 5/20 | 0.43 |
| ▸ | EPAS1 | Q99814 | 10/20 | 0.41 |
| ▸ | VEGFA | P15692 | 2/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.40 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.39 |
| ▸ | NR3C2 | P08235 | 1/20 | 0.39 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14861209 | 0.83 | SLC6A4 (0.49) | AREPAS1VEGFAMAPTKMT2A | |
| SCHEMBL352310 | 0.78 | KCNH2 (0.40) | ARKCNH2 | |
| SCHEMBL14861182 | 0.78 | AR (0.62) | AREPAS1VEGFAMAPTKMT2A | |
| SCHEMBL14861286 | 0.78 | SLC6A4 (0.55) | AREPAS1VEGFAMAPTKMT2A | |
| SCHEMBL4515241 | 0.77 | SLC6A4 (0.51) | AREPAS1MAPTKMT2AKCNH2 | |
| SCHEMBL13119726 | 0.77 | KCNH2 (0.44) | AREPAS1VEGFAMAPTKMT2A | |
| SCHEMBL12096582 | 0.74 | AR (0.54) | ARKCNH2 | |
| SCHEMBL4509069 | 0.73 | KCNH2 (0.44) | AREPAS1VEGFAMAPTKMT2A | |
| SCHEMBL12422184 | 0.73 | CA12 (0.61) | — | |
| SCHEMBL13119716 | 0.72 | KCNH2 (0.49) | EPAS1VEGFAMAPTKMT2ASLC22A12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090264425-A1 | CHEMICAL COMPOUNDS | PFIZER LIMITED | 2009-10-22 | — | — | US | disclosed |
| US-20090264425-A1 | CHEMICAL COMPOUNDS | PFIZER LIMITED | 2009-10-22 | — | — | US | disclosed |
| EP-1831157-A2 | NONNUCLEOSIDE INHIBITORS OF HIV-1 REVERSE TRANSCRIPTASE | Pfizer Limited (GB) | 2007-09-12 | — | — | EP | disclosed |
| WO-2006067587-A2 | NONNUCLEOSIDE INHIBITORS OF HIV-1 REVERSE TRANSCRIPTASE | PFIZER LIMITED (GB) | 2006-06-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090264425-A1 | CHEMICAL COMPOUNDS | POLR2E, POLR2A, POLRMT | AR 315/4885EPAS1 3133/4885VEGFA 4151/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.